Objectives: Abiraterone acetate and enzalutamide, novel anti-androgen therapies with distinct modes of action for the treatment of metastatic castration-resistant prostate cancer (mCRPC), are approved in both the pre-chemotherapy and postchemotherapy settings. These anti-androgen therapies have significantly improved outcomes among mCRPC patients. However, to date there is little published evidence regarding patients' real-world experience of these therapies in both the pre-chemotherapy or post-chemotherapy settings, particularly in terms of health-related quality of life (HRQoL) and treatment satisfaction. MethOds: Qualitative face-toface interviews were conducted with mCRPC patients (n= 38) and carers (n= 12) to obtain in-depth data concerning the patient experience with novel anti-androgen therapy. This included patients with experience of abiraterone acetate or enzalutamide in either the pre-chemotherapy or post-chemotherapy setting in France, Germany and the UK. Findings from this study have been used to inform the design of a larger quantitative, multinational online survey to further explore and quantify HRQoL and treatment satisfaction among mCRPC patients receiving anti-androgen therapy. Results: Patients generally had high expectations at initiation of therapy with a primary emphasis on reduction in prostate-specific antigen levels and improvements in HRQoL. Patients and carers reported that experiences on treatment had met or exceeded expectations. Administration procedures appeared to be of limited concern for patients and only mentioned by patients when prompted by directive questions. In particular, the need to take abiraterone acetate on an empty stomach was not deemed problematic. Some differences in the patient experience (e.g. side effects) and HRQoL of patients receiving abiraterone acetate and enzalutamide were noted and warrant further exploration. cOnclusiOns: Patients and carers reported largely positive experiences with novel anti-androgen therapies for the treatment of mCRPC. Potential differences between regimens in terms of treatment satisfaction and HRQoL are currently being explored in a larger quantitative online study.
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ReduCiNg tHe BaRRieRS tO CaPtuRiNg PatieNt RePORted OutCOmeS iN ONCOlOgy StudieS
Thilaganathan JA, O'Donohoe P CRF Health, London, UK Objectives: The FDA has previously noted that data reported directly by patients about how they are feeling and functioning (i.e. patient reported outcomes (PROs)) are rarely included in oncology drug labelling claims in the United States, with end points relating to survival, imaging and biomarkers tending to take priority. However, while research suggests an increase in PRO use in oncology trials, significant challenges remain and a low burden solution for all stakeholders is becoming increasingly important. MethOds: Key challenges for integrating PROs into oncology clinical trials were identified based on study protocols, sponsor feedback and best practices from previous oncology studies. Based on this feedback an electronic solution for capturing data in oncology studies was developed. Results: Patient and site burden were identified as key challenges in oncology studies deploying PROs. Oncology patients can be very impaired, so requiring the completion of lengthy questionnaires can result in non-compliance. A user focused electronic system reduces the burden of patients providing answers to questionnaires, and opens the possibility for data capture to occur at home rather than at study visits. Feedback also highlighted that sites struggle with organizing visits and staying protocol compliant. An electronic visit scheduling tool can help sites keep track of what order and at which visits questionnaires should be completed and to help remind and reschedule patient visits. cOnclusiOns: Obtaining a proper understanding of the patients experience in oncology clinical studies is increasingly becoming a priority for multiple stakeholders, not least the patients themselves. While there is evidence that the number of PROs being included in oncology studies is increasing over time there are still significant challenges to capturing high-quality PRO data. A holistic electronic solution, which considers both the patients and sites experience of providing data, can reduce the barriers to capturing high-quality PRO data. Objectives: Research on adherence, health outcomes and shared decision making all highlight the importance of understanding patient treatment preferences. However, a recent systematic review (Shingler et al., 2014) showed how little work has explored treatment preferences of oncology patients. The aim of the present study was to identify issues from previous patient preference research in oncology to design a novel protocol to explore treatment preferences of men with metastatic prostate cancer. MethOds: It was hypothesised that the low number of reported studies in oncology may be due to methodological issues encountered in studies. A review of stated preference research completed in oncology identified different issues. This information was then used to design a protocol for a patient preference study in men with metastatic castrate resistant prostate cancer. Results: Identified issues include (i) the use of inappropriate attributes (describing death, survival or progression), (ii) challenges with recruitment, sometimes associated symptoms, often painful and debilitating (Mughal et al. 2014) . Developed from the widely used MPN-SAF, the 7-item MPN-SAF TSS was modified with wording changes and by adding one tiredness item to better meet regulatory needs and assess symptom severity in myelofibrosis to support treatment benefit endpoints in clinical research. Study objectives were to translate the mMPN-SAF TSS into 21 languages for 26 countries and to assess comprehension and conceptual equivalence with the English source version in order to expand its use in global myelofibrosis research. MethOds: The mMPN-SAF TSS was translated following ISPOR guidelines for linguistic validation of PRO measures (Wild et al., 2005) using the universal approach (Wild et al., 2009 ). For each non-English language, two forward translations by native translators, reconciliation of forward translations, back-translation by one English-speaker fluent in the target language, and final reconciliation by a native-speaking language coordinator were conducted. Harmonization (i.e., comparison between languages for consistent interpretation) was performed to ensure conceptual equivalence across languages. Interviews were conducted with 4-5 native-speaking myelofibrosis patients for each language/country combination (N= 142). Interview data were analyzed qualitatively to assess linguistic and cultural validity in each language and confirm conceptual equivalence. Results: Mean age was 60 years (range 25-88); 51% were male. The translations were well understood and considered relevant with some patients raising minor issues during interviews. Patient feedback resulted in wording changes to the Bulgarian, Czech, Danish, Dutch, German, Hebrew, Hungarian, Japanese, Korean, Malay, Russian, Spanish, Simplified and Traditional Chinese versions. cOnclusiOns: All translated versions of the mMPN-SAF TSS were confirmed to be conceptually equivalent and well understood in the 26 countries evaluated. These translations fill a significant need for patientfocused instruments in local languages to facilitate future myelofibrosis research worldwide. The translation process revealed minor cultural differences between the translations of the TESS, which required adjustments. The MSTS translated well. After evaluating the measurement outcomes, the median TESS and MSTS scores were 85.5% (range, 51.5-100.0%) and 76.7% (range, 26.7-100.0%), respectively. In both outcome measures, the authors noted a 5% ceiling effect. cOnclusiOns: The pilot testing of the Finnish translation of the lower-limb TESS and MSTS indicated a good functional outcome in most patients who underwent lower limb-sparing surgery for STS. The TESS and the MSTS measurement outcomes correlated relatively closely. The psychometric properties of the Finnish versions of the lower-limb TESS and MSTS warrant further studying.
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PCN235 tHe fiNNiSH veRSiONS Of tHe lOweR-limB SeCtiONS
PCN236 BReaSt CaNCeR PatieNtS' PeRCePtiON ON HealtH imPaCtS fROm ReCeiviNg CHemOtHeRaPy
Areepium N Chulalongkorn University, Bangkok, Thailand Objectives: Receiving chemotherapy causes moderate to severe adverse events which deteriorate to both body and mind of breast cancer patients. Some questionnaires were developed to measure breast cancer patients' quality of life e.g., the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, the Functional Assessment of Cancer Therapy for Breast cancer (FACT-B) . Howereve, those questionnaires were rarely used in routine practice due to time consuming in difficulty in outcome evaluation. Therefore, we need to develop the practical questionnaire to evaluate impacts of chemotherapy on the overall health status in breast cancer patients' view. MethOds: We develop the questionnaire focusing on the symptoms related to adverse reaction of chemotherapy which patients felt and correlate with activity of daily living. The questionnaire consisted of 16 items for patients to answer with 5 likert scale (strongly disagree 0 to strongly agree 4). The possible highest score were 64 and the higher score was the more suffering from chemotherapy in patients' perspective. Results: One hundred breast cancer patients were interviewed. The average interview time was only 5-10 minutes per patient. Average age of patients were 52.09 ±12.77 years old and majority of them (71%) had stage I to III breast cancer. The average score was 23.06 + 13.27 (minimum score was 0 and maximum score was 57 out of 64). we found the highest score (2.32 + 1.67) that patient reported for impacts on their heath from chemotherapy was "I am tried easier" and the lowest score (0.56 + 1.21) patient reported was "it is hard to breathe". The factors associated with total score of questionnaire were adverse reactions. cOnclusiOns: Our questionnaire can be used as a screening tool to classify patients according to severity and urgency for providing pharmaceutical care especially in the practice sites with limited manpower of clinical pharmacists.
